Supplementary Methods, Figures 1 - 7 from HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab

Suthinee Ithimakin,Kathleen C. Day,Fayaz Malik, Qin Zen, Scott J. Dawsey, Tom F. Bersano-Begey, Ahmed A. Quraishi, Kathleen Woods Ignatoski,Stephanie Daignault, April Davis, Christopher L. Hall,Nallasivam Palanisamy, Amber N. Heath, Nader Tawakkol, Tahra K. Luther,Shawn G. Clouthier, Whitney A. Chadwick,Mark L. Day,Celina G. Kleer,Dafydd G. Thomas, Daniel F. Hayes,Hasan Korkaya,Max S. Wicha

crossref(2023)

引用 0|浏览19
暂无评分
摘要

PDF file - 491K, Supplementary Figure 3. Effect of trastazumab on stem cell marker expression. Supplementary Figure 2. Trastuzumab inhibits tertiary tumorsphere formation in luminal cell lines. Supplementary Figure 1. Representative FACS analysis demonstrating an overlap between HER2 expression and ALDH activity. Supplementary Figure 4. Trastuzumab treatment or HER2 gene knockdown reduces tumorsphere formation of MCF7 cells. Supplementary Figure 5. Rank mediated upreglation of HER2 expression in MCF7 cells. Supplementary Figure 6. Elevated HER2 expression in bone metastasis compared to matched primary luminal tumors is not due to HER2 gene amplification. Supplemental Figure 7. No significant differences in HER2 protein expression were found in matched primary tumors and bone metastasis in women with HER-positive breast cancer.

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要